A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut

Molecular Pharmaceutics

Volumn 9, Issue 11, 2012, Pages 3246-3258

  Xia, Bijun ^a   Zhou, Qiong ^a   Zheng, Zhijie ^a   Ye, Ling ^a   Hu, Ming ^a,b   Liu, Zhongqiu ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

flavonoid bioavailability; intestine; local recycling; phase II metabolism; phenolic

Indexed keywords

FLAVONOID; GLUCONOLACTONE; MICROBIAL ENZYME; SACCHAROLACTONE; UNCLASSIFIED DRUG; WOGONIN; WOGONOSIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RETENTION; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSPORT; DUODENUM; HYDROLYSIS; INTESTINE ABSORPTION; JEJUNUM; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; FLAVANONES; GASTROINTESTINAL TRACT; GLUCARIC ACID; GLUCONATES; GLUCURONIDASE; GLUCURONIDES; GLYCOSYLCERAMIDASE; HUMANS; INTESTINAL ABSORPTION; JEJUNUM; KINETICS; LACTONES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECYCLING; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84868566482     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300315d     Document Type: Article

References (37)

1. Hu, M. Commentary: bioavailability of flavonoids and polyphenols: call to arms Mol. Pharmaceutics 2007, 4 (6) 803-6
2. Manwaring, W. H. Enterohepatic Circulation of Estrogens Calif. West. Med. 1943, 59 (5) 257
3. Chen, J.; Lin, H.; Hu, M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition J. Pharmacol. Exp. Ther. 2003, 304 (3) 1228-35
4. Dai, J. Y.; Yang, J. L.; Li, C. Transport and metabolism of flavonoids from Chinese herbal remedy Xiaochaihu-tang across human intestinal Caco-2 cell monolayers Acta Pharmacol. Sin. 2008, 29 (9) 1086-93
5. Kim, Y. H.; Jeong, D. W.; Kim, Y. C.; Sohn, D. H.; Park, E. S.; Lee, H. S. Pharmacokinetics of baicalein, baicalin and wogonin after oral administration of a standardized extract of Scutellaria baicalensis, PF-2405 in rats Arch. Pharm. Res. 2007, 30 (2) 260-5
6. Fas, S. C.; Baumann, S.; Zhu, J. Y.; Giaisi, M.; Treiber, M. K.; Mahlknecht, U.; Krammer, P. H.; Li-Weber, M. Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis Blood 2006, 108 (12) 3700-6
7. Rushworth, S. A.; Micheau, O. Molecular crosstalk between TRAIL and natural antioxidants in the treatment of cancer Br. J. Pharmacol. 2009, 157 (7) 1186-8
8. Lee, D. H.; Kim, C.; Zhang, L.; Lee, Y. J. Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells Biochem. Pharmacol. 2008, 75 (10) 2020-33
9. Lee, D. H.; Rhee, J. G.; Lee, Y. J. Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin Br. J. Pharmacol. 2009, 157 (7) 1189-202
10. Rugo, H.; Shtivelman, E.; Perez, A.; Vogel, C.; Franco, S.; Tan Chiu, E.; Melisko, M.; Tagliaferri, M.; Cohen, I.; Shoemaker, M.; Tran, Z.; Tripathy, D. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer Breast Cancer Res. Treat. 2007, 105 (1) 17-28
11. Kawashima, K.; Nomura, A.; Makino, T.; Saito, K.; Kano, Y. Pharmacological properties of traditional medicine (XXIX): effect of Hange-shashin-to and the combinations of its herbal constituents on rat experimental colitis Biol. Pharm. Bull. 2004, 27 (10) 1599-603
12. Ahmed-Belkacem, A.; Ahnou, N.; Barbotte, L.; Wychowski, C.; Pallier, C.; Brillet, R.; Pohl, R. T.; Pawlotsky, J. M. Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase Gastroenterology 2010, 138 (3) 1112-22
13. Ferenci, P.; Scherzer, T. M.; Kerschner, H.; Rutter, K.; Beinhardt, S.; Hofer, H.; Schoniger-Hekele, M.; Holzmann, H.; Steindl-Munda, P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy Gastroenterology 2008, 135 (5) 1561-7
14. Polyak, S. J.; Morishima, C.; Shuhart, M. C.; Wang, C. C.; Liu, Y.; Lee, D. Y. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin Gastroenterology 2007, 132 (5) 1925-36
15. Sukhthankar, M.; Yamaguchi, K.; Lee, S. H.; McEntee, M. F.; Eling, T. E.; Hara, Y.; Baek, S. J. A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer Gastroenterology 2008, 134 (7) 1972-80
16. Jia, X.; Chen, J.; Lin, H.; Hu, M. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates J. Pharmacol. Exp. Ther. 2004, 310 (3) 1103-13
17. Lin, Y. T.; Hsiu, S. L.; Hou, Y. C.; Chen, H. Y.; Chao, P. D. Degradation of flavonoid aglycones by rabbit, rat and human fecal flora Biol. Pharm. Bull. 2003, 26 (5) 747-51
18. Marshall, T.; Williams, K. M. Comparison of Coomassie Brilliant Blue protein dye-binding assays for determination of urinary protein concentration Clin. Chem. 1987, 33 (4) 577-8
19. Ausubel, F. M.; Brent, R.; Kingston, R. E.; Moore, D. D.; Seidman, J. G.; Smith, J. A.; Struhl, K. Current Protocols in Molecular Biology; John Wiley & Sons, New York, 1988; Vol. 1, pp 1.3.1-4.
20. Yi, J. H.; Ni, R. Y.; Luo, D. D.; Li, S. L. Intestinal flora translocation and overgrowth in upper gastrointestinal tract induced by hepatic failure World J. Gastroenterol. 1999, 5 (4) 327-9
21. China Pharmacopeia, 2 nd ed.; 2005; Appendix XI J, pp 93-5.
22. Wang, S. W.; Chen, J.; Jia, X.; Tam, V. H.; Hu, M. Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties Drug Metab. Dispos. 2006, 34 (11) 1837-48
23. Liu, Y.; Liu, Y.; Dai, Y.; Xun, L.; Hu, M. Enteric disposition and recycling of flavonoids and ginkgo flavonoids J. Altern. Complementary Med. 2003, 9 (5) 631-40
24. Liu, Z.; Hu, M. Natural polyphenol disposition via coupled metabolic pathways Expert Opin. Drug Metab. Toxicol. 2007, 3 (3) 389-406
25. Terao, J. Dietary flavonoids as antioxidants in vivo: conjugated metabolites of (-)-epicatechin and quercetin participate in antioxidative defense in blood plasma J. Med. Invest. 1999, 46 (3-4) 159-68
26. Yamamoto, N.; Moon, J. H.; Tsushida, T.; Nagao, A.; Terao, J. Inhibitory effect of quercetin metabolites and their related derivatives on copper ion-induced lipid peroxidation in human low-density lipoprotein Arch. Biochem. Biophys. 1999, 372 (2) 347-54
27. Jeong, E. J.; Liu, X.; Jia, X.; Chen, J.; Hu, M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions Curr. Drug Metab. 2005, 6 (5) 455-68
28. Zhang, L.; Zuo, Z.; Lin, G. Intestinal and hepatic glucuronidation of flavonoids Mol. Pharmaceutics 2007, 4 (6) 833-45
29. Wolfson, P.; Hoffmann, D. L. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers Altern. Ther. Health Med. 2003, 9 (2) 74-8
30. Ghosal, A.; Hapangama, N.; Yuan, Y.; Achanfuo-Yeboah, J.; Iannucci, R.; Chowdhury, S.; Alton, K.; Patrick, J. E.; Zbaida, S. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia) Drug Metab. Dispos. 2004, 32 (3) 314-20
31. Kosoglou, T.; Statkevich, P.; Johnson-Levonas, A. O.; Paolini, J. F.; Bergman, A. J.; Alton, K. B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions Clin. Pharmacokinet. 2005, 44 (5) 467-94
32. Jeong, E. J.; Liu, Y.; Lin, H.; Hu, M. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of ugt1a10 Drug Metab. Dispos. 2005, 33 (6) 785-94
33. Levi, M. S.; Borne, R. F.; Williamson, J. S. A review of cancer chemopreventive agents Curr. Med. Chem. 2001, 8 (11) 1349-62
34. Logan, R. M.; Gibson, R. J.; Bowen, J. M.; Stringer, A. M.; Sonis, S. T.; Keefe, D. M. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis Cancer Chemother. Pharmacol. 2008, 62 (1) 33-41
35. Nagano, T.; Yasunaga, M.; Goto, K.; Kenmotsu, H.; Koga, Y.; Kuroda, J.; Nishimura, Y.; Sugino, T.; Nishiwaki, Y.; Matsumura, Y. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment Clin. Cancer Res. 2009, 15 (13) 4348-55
36. Brill, S. S.; Furimsky, A. M.; Ho, M. N.; Furniss, M. J.; Li, Y.; Green, A. G.; Bradford, W. W.; Green, C. E.; Kapetanovic, I. M.; Iyer, L. V. Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms J. Pharm. Pharmacol. 2006, 58 (4) 469-79
37. Walle, T.; Hsieh, F.; DeLegge, M. H.; Oatis, J. E., Jr.; Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans Drug Metab. Dispos. 2004, 32 (12) 1377-82